Insight Molecular Diagnostics Inc. Tenant Improvements
Insight Molecular Diagnostics Inc. (IMDX) had Tenant Improvements of $1.30 million as of 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Balance Sheet › Assets
us-gaap:TenantImprovements · last filed 2021-05-17
- 2021-03-31: Tenant Improvements $1.30M.
- 2020-12-31: Tenant Improvements $1.30M.
- 2020-09-30: Tenant Improvements $1.30M.
| Period end | Tenant Improvements |
|---|---|
| 2021-03-31 | $1.30M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $1.30M 10-K · filed 2021-03-19 |
| 2020-09-30 | $1.30M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |